Tech4Humanity AtlasGround ZeroCurrent ThemesFuture ResearchGalleryLive Q&ASearch

Biological & Neural Integrity / Neurotechnology and BCI

SUB-T05-007 · Evidence — SEEDED / PARTIAL — defensible non-empirical baseline; validation and replayable search outstanding

BCI Safety

1. Hypothesis

A transparent, safety-bounded and person-centred approach to bci safety, combining validated measurement, informed consent, privacy and security controls, human oversight and longitudinal monitoring, will improve benefit–risk outcomes compared with opaque or technology-centred approaches.

2. Experiment design

Design: prospective mixed-method BCI validation study with baseline, repeated-use and longitudinal adaptation phases focused on BCI Safety Methods: controlled BCI task testing; signal-quality analysis; calibration studies; longitudinal cohort follow-up; usability and accessibility testing; human-factors analysis; adverse-event monitoring; expert and affected-user review; reproducibility testing; methods adapted specifically to BCI Safety Independent variables: technology type; exposure or intervention intensity; duration; assurance controls; human oversight; user characteristics; operating context Dependent variables: functional outcome; biological or neural safety; user agency; privacy; reliability; recovery; subtopic-specific outcome for prevention, detection and management of physical, cognitive, psychological and functional BCI harms Confounders: age; health; disability; medication; prior experience; baseline physiology; environment; device quality; clinician or operator expertise; socioeconomic access Measures: decoding accuracy; information-transfer rate; calibration time; task success; fatigue; cognitive load; accessibility; adverse events; adaptation stability; validated subtopic measures for prevention, detection and management of physical, cognitive, psychological and functional BCI harms; subgroup effects; false-positive and false-negative rates; user-reported burden Success criteria: Statistically and clinically or practically meaningful benefit; acceptable adverse-event profile; preserved agency and privacy; no disproportionate subgroup harm; reproducible performance; explicit safety limits; effective recovery and human escalation. Failure conditions: No meaningful benefit; biological, neural, psychological, privacy or rights harm exceeds benefit; performance fails outside narrow conditions; unsafe dependency emerges; consent or refusal is compromised; incidents cannot be detected, reversed or remediated.

3. Seed result / current evidence

DEFENSIBLE SEED RESULT — NON-EMPIRICAL. The current evidence supports BCI Safety as a testable research proposition. Problem basis: BCI systems can improve communication, mobility and capability, but performance, calibration, usability, safety and long-term adaptation vary substantially across people and contexts. The specific unresolved issue is prevention, detection and management of physical, cognitive, psychological and functional BCI harms. Directional expectation: If supported, the proposed approach should improve functional outcome; biological or neural safety; user agency; privacy; reliability; recovery; subtopic-specific outcome for prevention, detection and management of physical, cognitive, psychological and functional BCI harms while reducing adverse effects, misuse, exclusion, dependency and recovery time. Proposed observations: decoding accuracy; information-transfer rate; calibration time; task success; fatigue; cognitive load; accessibility; adverse events; adaptation stability; validated subtopic measures for prevention, detection and management of physical, cognitive, psychological and functional BCI harms; subgroup effects; false-positive and false-negative rates; user-reported burden. Seed data profile: Evidence Strength 10/100; Confidence 25/100; Maturity 20/100; Overall Health 35/100; Novelty 80/100; Strategic Importance 95/100. Evidence boundary: No validated results yet.; experiments 0, studies 0, participants 0. This is suitable for protocol formation and baseline comparison, not as a finding of effect.

4. Seed conclusion

DEFENSIBLE SEED CONCLUSION — PROVISIONAL. BCI Safety warrants structured testing because the CSV identifies a defined problem, falsifiable hypothesis, measurable outcomes and relevant literature foundations. The present position is that “A transparent, safety-bounded and person-centred approach to bci safety, combining validated measurement, informed consent, privacy and security controls, human oversight and longitudinal monitoring, will improve benefit–risk outcomes compared with opaque or technology-centred approaches.” is plausible and decision-relevant, but unvalidated. Proceed to controlled testing against the stated success and failure conditions. Confirm, narrow or reject this seed after effect sizes, uncertainty, subgroup outcomes, adverse effects, persistence and handback performance are observed.

Prior-art search performed before starting

PRIOR-ART SEED BASELINE — PARTIAL. The CSV records these literature domains: Neuroscience; neurotechnology; physiology; medical-device safety; rehabilitation; cybersecurity; bioethics; human rights; literature specific to BCI Safety. It also records: U.S. FDA Brain-Computer Interface guidance — https://www.fda.gov/; IEEE Neuroethics Framework — https://standards.ieee.org/; NIH BRAIN Initiative — https://braininitiative.nih.gov/; WHO medical-device safety — https://www.who.int/health-topics/medical-devices. Evidence register status: “Seeded; authoritative source register initiated; empirical evidence not yet ingested”. This is defensible as a starting prior-art inventory, but not as proof of a completed systematic search because search dates, databases, exact queries, reviewer, result counts, screening decisions, claim mapping and a replayable receipt are absent.

Prior-art material named: Existing literature: Neuroscience; neurotechnology; physiology; medical-device safety; rehabilitation; cybersecurity; bioethics; human rights; literature specific to BCI Safety. References: U.S. FDA Brain-Computer Interface guidance — https://www.fda.gov/; IEEE Neuroethics Framework — https://standards.ieee.org/; NIH BRAIN Initiative — https://braininitiative.nih.gov/; WHO medical-device safety — https://www.who.int/health-topics/medical-devices

Critical gap / next action

Create and attach a dated prior-art search log; lock the protocol; execute the proposed study; link raw data and analysis; then replace the results and conclusion placeholders with evidence-bounded findings.

Evidence classification: SEEDED / PARTIAL — defensible non-empirical baseline; validation and replayable search outstanding — provisional research record, not a validated finding.